Navigation Links
Hovione's TwinCaps(R) Inhaler in Phase III Clinical Trials for Influenza
Date:4/15/2009

n use, the shuttle is moved to one side by the patient to align one chamber of the shuttle with the mouth piece to allow the first inhalation, creating turbulence within the dose chamber and drawing the dry powder into the lung of the patient. The process is then repeated for the second dose chamber, as the shuttle is moved to the opposite side to permit another inhalation to take place. Visit http://www.hovione.com/twincaps.

Daiichi Sankyo has indicated that they are planning to file NDA in Japan in March 2010 and get approval within 2010, while Daiichi Sankyo and Biota are seeking licensees for the drug product collaboratively for the rest of world market. Hovione retains the right to commercialize TwinCaps(R) outside the field of influenza.

Peter Villax, Hovione's Vice President Pharma Business Unit stated "The unique design benefits of TwinCaps(R) including high dose capability, disposability and low cost are predicted to drive growth in Hovione's inhalation business and further leverage our already proven track record in developing inhalation APIs, formulation development and manufacturing services."

About Hovione. Hovione is an international company with 50 years' experience in Active Pharmaceutical Ingredient development and compliant manufacture. With four FDA inspected sites in the US, China, Ireland and Portugal the company focuses on the most demanding customers, in the most regulated markets. The company also offers integrated API, particle design and formulation development and manufacturing. In the inhalation area, Hovione is the only independent company offering such a broad range of services.

For more information about Hovione, please visit the Hovione site at http://www.hovione.com or contact Corporate Communications, Isabel Pina, +351-21-982-9362, e-mail: '/>"/>

SOURCE Hovione
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. MicroDose and Nexus6 Announce Collaboration to Evaluate Application of Remote Patient Compliance Monitoring Technology with MicroDoses Electronic Dry Powder Inhaler
2. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
3. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
6. Evotec to Present Details of the Positive Phase II Study in Insomnia With EVT 201 at the Worldsleep07 Congress in Cairns/Australia
7. Phase III Trial Finds Pharmaxis Bronchitol Effective
8. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer
9. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
10. Exelixis Reports Encouraging Interim Data From a Phase 2 Trial of XL647 as First-Line Therapy for Non-Small Cell Lung Cancer
11. Evotec Reports Details of the Positive Proof-of-Concept Phase II Study in Insomnia With EVT 201
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... MA (PRWEB) January 22, 2015 zFlo ... is pleased to announce an exciting product from a new ... motion analysis solutions over the past 15 years, with offerings ... Most recently, their 3D IMU system (inertial measurement unit), iSen, ...
(Date:1/22/2015)... Diagenode, Inc., a leading global provider ... complete solutions for epigenetics research, recently launched a ... need for manual processing. The new ChIPettor System ... histones or transcription factors and a semi-automated pipette ...
(Date:1/22/2015)... , a precision medicine software company that has developed a ... genomic, imaging and other biomedical data in research and clinical ... CEO of Aspera, an IBM Company, to its board as ... "We are pleased to welcome Michelle to ...
(Date:12/24/2014)... YORK , Dec. 24, 2014 PlasmaTech Biopharmaceuticals, Inc. ... critical areas, announced the closing of an underwritten public offering ... up to an aggregate 3,500,000 shares of common stock, at ... warrant.  The warrants have a per share exercise price of ...
Breaking Biology Technology:3D Motion Capture Just Got Easy 2Diagenode Launches Unique Semi-Automated Solution for Chromatin Immunoprecipitation 2GenoSpace Expands Board with Appointment of Michelle Munson 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 2PlasmaTech Biopharmaceuticals, Inc. Announces Closing of Public Offering 3
... , EAST GRINSTEAD, West Sussex, U.K. and CLEVELAND, ... Biosciences business and premier provider of diagnostic systems ... its East Grinstead, U.K., manufacturing and research and ... its Sensititre® product line for susceptibility and identification ...
... MISSISSAUGA, ON, Nov. 18 /PRNewswire-FirstCall/ - YM BioSciences Inc. ... sciences product development company that identifies and advances a ... of development, announced that results from a study evaluating ... 2009 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics conference in ...
... Fla., Nov. 18 Algenol Biofuels LLC, developers of ... Linde Group have agreed to collaborate in a joint ... of carbon dioxide (CO2) and oxygen (O2) for Algenol,s ... the companies join forces to develop cost-efficient technologies that ...
Cached Biology Technology:TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 2TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 3TREK Diagnostic Systems Opens New U.K. Facility in East Grinstead to Meet Expanded Customer Demand for Microbiology Products 4YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 2YM BIOSCIENCES ANNOUNCES NIMOTUZUMAB RESULTS IN ADVANCED TRIPLE-NEGATIVE BREAST CANCER MODEL PRESENTED AT AACR-NCI-EORTC MEETING 3Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 2Algenol Biofuels and The Linde Group Agree To Cooperate in CO2 and O2 Management For Biofuel Production From Algae 3
(Date:12/19/2014)... DUBLIN , Dec. 18, 2014 Research and Markets ... of the "iPhone 5S Fingerprint Sensor - Apple/AuthenTec ... their offering. http://photos.prnewswire.com/prnh/20130307/600769 ... 2012, Apple introduced the fingerprint reading feature with the ...
(Date:12/19/2014)... 2014   LaunchKey , the first decentralized mobile authentication ... of Things era, today announced the close of $3 ... led by Metamorphic Ventures with participation from ENIAC Ventures, ... others.  LaunchKey has raised $4 million to date, and ...
(Date:12/17/2014)... 2014  HITLAB SM announced today its completion of ... adherence to current U.S. Food and Drug Administration (FDA) ... device and smart phone application trials utilizing the highest ... "HITLAB is determined to improve global healthcare access, quality, ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... Molecular Imaging Labs (MI Labs) have succeeded in combining ... of equipment. These techniques are particularly useful for cancer ... microSPECT. SPECT and PET can be performed simultaneously and ... microPET. The new device is known as the VECTor ...
... Properties SA announces the winners of the Reaxys PhD ... PhD or having completed a PhD within the last ... the fields of organic, organometallic and inorganic chemistry. ... launched in January 2010. Submissions consisted of a representative ...
... Navarra, the Polytechnic University of Madrid (CBGP), the University ... Institute of Agricultural Research have managed to sequence the ... olive tree. The study, included in the June issue ... of the genome of a pathogenic bacteria undertaken in ...
Cached Biology News:TU Delft and MI Labs merge PET and SPECT biomedical imaging techniques and increase resolution 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 2The Reaxys Ph.D. Prize awards innovative research in organic, organometallic and inorganic chemistry 3Genome of bacteria responsible for tuberculosis of olive tree sequenced 2
This Malachite Green Phosphate Detection Kit...
Request Info...
Request Info...
... Western Blot Analysis Kit is an ... developed by Biochain. It detects protein ... or yoctomole (10 -24 M) ... parts: Millennium Enhancer, protein interaction system ...
Biology Products: